Clinical Trial Update: To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the optimal dose of the PET imaging agent 68Ga-OPS202 in gastroenteropancreatic neuroendocrine tumors has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• 68Ga-OPS202

Snippet

Sponsor: Ipsen | Conditions: Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | Status: COMPLETED | Results posted: 2021-01-14